心脏大血管手术围术期镇痛镇静方案比较-丙泊酚对比艾司氯胺酮

注册号:

Registration number:

ChiCTR2500097877 

最近更新日期:

Date of Last Refreshed on:

2025-02-26 16:49:02 

注册时间:

Date of Registration:

2025-02-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

心脏大血管手术围术期镇痛镇静方案比较-丙泊酚对比艾司氯胺酮

Public title:

Comparison of perioperative analgesic and sedative regimens in cardiac vascular surgery - Propofol versus esketamine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

心脏大血管手术围术期镇痛镇静方案比较-丙泊酚对比艾司氯胺酮

Scientific title:

Comparison of perioperative analgesic and sedative regimens in cardiac vascular surgery - Propofol versus esketamine

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

康慧 

研究负责人:

康慧 

Applicant:

Hui Kang 

Study leader:

Hui Kang 

申请注册联系人电话:

Applicant telephone:

+86 138 8190 7302

研究负责人电话:

Study leader's
telephone:

+86 138 8190 7302

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

kkzaihuaxi@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

kkzaihuaxi@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国四川省成都市外南国学巷37号

研究负责人通讯地址:

中国四川省成都市外南国学巷37号

Applicant address:

37 Guoxue Avenue, Chengdu ,Sichuan, China

Study leader's address:

37 Guoxue Avenue, Chengdu ,Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023年审(2457)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Biomedical Ethics Review Committee, West China Hospital, Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-01 00:00:00

伦理委员会联系人:

邓绍林

Contact Name of the ethic committee:

Shaolin Deng

伦理委员会联系地址:

四川省成都市武侯区国学巷37号老八教412室

Contact Address of the ethic committee:

Room 412, LaoBajiao, No.37 Guoxue Lane, Wuhou District, Chengdu, Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 8542 3237

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院心脏大血管外科

Primary sponsor:

Department of Cardiac Vascular Surgery, West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

中国四川省成都市外南国学巷37号

Primary sponsor's address:

37 Guoxue Avenue, Chengdu ,Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

中国四川省成都市外南国学巷37号 

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Avenue, Chengdu ,Sichuan, China

经费或物资来源:

江苏恒瑞医药股份有限公司

Source(s) of funding:

Jiangsu Hengrui Pharmaceutical Co., LTD

研究疾病:

心脏大血管手术  

Target disease:

cardiac vascular surgery

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

心脏大血管手术围术期两种镇痛镇静方案比较-丙泊酚对比艾司氯胺酮, 对心脏大血管外科患者术后延长机械通气的影响。  

Objectives of Study:

Compared with two analgesic and sedative regimens: the effect ofpropofol versus Esketamine on prolonged mechanical ventilation in patients undergoing cardiac vascular surgery during perioperative period.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

排除标准:(1)高血压SBP≥180mmHg或正在静脉使用降压药。(2)快速型心律失常。(3)室性心律失常。(4)缺血性心肌病。(5)主动脉瓣重度狭窄且未经手术解除狭窄。(6)颅内压升高。(7)未经治疗的甲状腺功能亢进。(8)严重精神障碍病史。(9)青光眼或穿透性眼外伤。(10)正在使用氨茶碱或茶碱缓释片。

Exclusion criteria:

Exclusion criteria: (1) Hypertension SBP >= 180mmHg or intravenous antihypertensive drugs being used. (2) Tachyarrhythmia. (3) Ventricular arrhythmia. (4) Ischemic cardiomyopathy. (5) Severe aortic stenosis without surgical removal. (6) Increased intracranial pressure. (7) Untreated hyperthyroidism (8) History of serious mental disorders. (9) Glaucoma or penetrating eye trauma. (10) aminophylline or theophylline sustained release tablets are being used.

研究实施时间:

Study execute time:

From 2025-03-15 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-15 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

实验组 

样本量:

79

Group:

Experimental group

Sample size:

干预措施:

艾司氯胺酮+布托啡诺iv泵入

干预措施代码:

S

Intervention:

Esketamine + Butorphanol iv is pumped in

Intervention code:

组别:

对照组

样本量:

79

Group:

Control group

Sample size:

干预措施:

丙泊酚+布托啡诺 iv泵入

干预措施代码:

P

Intervention:

Pump in propofol + butorphanol iv

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三级 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

level 3

测量指标:

Outcomes:

指标中文名:

机械通气时间

指标类型:

主要指标

Outcome:

Mechanical ventilation time

Type:

Primary indicator

测量时间点:

入ICU至术后30天

测量方法:

临床数据

Measure time point of outcome:

from admitted to ICU until 30 days after surgery

Measure method:

clinical data

指标中文名:

快速通道失败率

指标类型:

次要指标

Outcome:

Fast track failure rate

Type:

Secondary indicator

测量时间点:

入ICU至术后30天

测量方法:

临床数据

Measure time point of outcome:

from admitted to ICU until 30 days after surgery

Measure method:

clinical data

指标中文名:

无创呼吸机时间

指标类型:

次要指标

Outcome:

Non-invasive ventilation time

Type:

Secondary indicator

测量时间点:

入ICU至术后30天

测量方法:

临床数据

Measure time point of outcome:

from admitted to ICU until 30 days after surgery

Measure method:

clinical data

指标中文名:

ICU时间

指标类型:

次要指标

Outcome:

ICU time

Type:

Secondary indicator

测量时间点:

入ICU至术后30天

测量方法:

临床数据

Measure time point of outcome:

from admitted to ICU until 30 days after surgery

Measure method:

clinical data

指标中文名:

气管切开

指标类型:

次要指标

Outcome:

tracheotomy

Type:

Secondary indicator

测量时间点:

入ICU至术后30天

测量方法:

临床数据

Measure time point of outcome:

from admitted to ICU until 30 days after surgery

Measure method:

clinical data

指标中文名:

器官功能衰竭

指标类型:

次要指标

Outcome:

Organ failure

Type:

Secondary indicator

测量时间点:

入ICU至术后30天

测量方法:

试验室检测及临床数据

Measure time point of outcome:

admitted to ICU until 30 days after surgery

Measure method:

Laboratory test and clinical data

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机表

Randomization Procedure (please state who generates the random number sequence and by what method):

Stochastic table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

患者盲法

Blinding:

Patient blindness

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2027年公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Open in 2027

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-02-26 16:48:56